Mechanism insights into the pleiotropic effects of nobiletin as a potential therapeutic agent on non-alcoholic fatty liver disease (NAFLD)

被引:1
|
作者
Ran, Qiqi [1 ]
Gan, Qianrong [1 ]
Zhu, Ye [2 ]
Song, Li [1 ]
Shen, Longyu [1 ]
Duan, Xinyi [1 ]
Zhu, Xinyun [3 ]
Huang, Wei [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu 611137, Peoples R China
[2] Hainan Med Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Hainan 570102, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Chengdu 611137, Peoples R China
基金
美国国家科学基金会;
关键词
Non-alcoholic fatty liver disease; Nobiletin; Lipid metabolism; Insulin resistance; Anti-inflammatory; Anti-oxidation; CITRUS FLAVONOIDS; OXIDATIVE STRESS; PATHOGENESIS; CHOLESTEROL; INFLAMMATION; METABOLITES; INSULIN; CELLS; 4'-DEMETHYLNOBILETIN; 5-DEMETHYLNOBILETIN;
D O I
10.1016/j.biopha.2024.116322
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases and is emerging as one of the fastest-growing causes of liver-related deaths worldwide. It is necessary to find strategies to effectively prevent and treat NAFLD, as no definitive drug has been approved. Nobiletin (NOB) is the critical active ingredient of Chinese herbal medicines such as Citrus aurantium and Citri Reticulatae Pericarpium, which have antiinflammatory, antioxidant, lipid regulating, and insulin resistance regulating effects. Numerous studies have demonstrated that NOB can prevent and treat the onset and progression of NAFLD. In this review, the mechanisms of NOB for treating NAFLD have been summarized, hoping to provide a basis for subsequent studies of NOB and to provide a research ground for the development of therapeutic drugs for NAFLD.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Beneficial effects of raisin consumption in patients with non-alcoholic fatty liver disease (NAFLD)
    Stoupaki, Maria
    Diolintzi, Anastasia
    Kokkinos, Alexander
    Kaliora, Andriana
    Gioxari, Aristea
    Kanellos, Panagiotis
    Revenas, Konstantinos
    Tentolouris, Nicholas
    Ladas, Spyridon
    Karathanos, Vaios
    ANNALS OF NUTRITION AND METABOLISM, 2015, 67 : 466 - 466
  • [42] EFFECTS OF VITAMIN D SUPPLEMENTATION ON PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Taghvaei, Tarang
    Akha, Ozra
    Mouodi, Marjan
    Fakheri, Hafez Tirgar
    Kashi, Zahra
    Maleki, Iradj
    Mohammadpour, Rezaali
    ACTA MEDICA MEDITERRANEA, 2018, 34 (02): : 415 - 422
  • [43] Leptin as a marker of liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
    Petrovic, LM
    Alba, LM
    Lindor, KD
    Talwakar, JA
    Angulo, P
    LABORATORY INVESTIGATION, 2003, 83 (01) : 283A - 283A
  • [44] Leptin as a marker of liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
    Petrovic, LM
    Alba, LM
    Lindor, KD
    Talwakar, JA
    Angulo, P
    MODERN PATHOLOGY, 2003, 16 (01) : 283A - 283A
  • [45] Liver Biopsy and Non-alcoholic Fatty Liver Disease (NAFLD) in Bariatric Patients
    Kanakala, V.
    Chattopadhyay, D.
    Sarkar, R.
    Balupuri, S.
    Small, P. K.
    BRITISH JOURNAL OF SURGERY, 2015, 102 : 285 - 285
  • [46] Therapeutic Potential of Herbal Medicine against Non-alcoholic Fatty Liver Disease
    Pourali, Ghazaleh
    Hosseini, Zeinab S.
    Maftooh, Mina
    Nazari, Elham
    Khazaei, Majid
    Nassiri, Mohammadreza
    Hassanian, Seyed M.
    Ghayour-Mobarhan, Majid
    Ferns, Gordon A.
    Kiani, Mohammad A.
    Avan, Amir
    CURRENT DRUG TARGETS, 2023, 24 (04) : 300 - 319
  • [47] Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease
    Tan, Panli
    Jin, Li
    Qin, Xiang
    He, Beihui
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [48] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
    Schattenberg, Joern M.
    ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
  • [49] In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kanuri, Giridhar
    Bergheim, Ina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (06): : 11963 - 11980
  • [50] Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
    Cole, Banumathi K.
    Feaver, Ryan E.
    Wamhoff, Brian R.
    Dash, Ajit
    EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (02) : 193 - 205